ProRelix Research

MAY 11, 2025

Stay informed on essential regulations governing Nutraceutical Clinical Trials in India, with a detailed look at ethical standards, CDSCO oversight, and trial conduct protocols. Indias nutraceutical sector is experiencing […] The post Regulations on Nutraceutical Clinical Trials in India Must-Know Facts appeared first on ProRelix Research.

Clinical Trials 52

Clinical Trials Regulations Trials Government 52

Drugs.com

MAY 11, 2025

SUNDAY, May 11, 2025 Why does sugar taste so good and why do we want it so badly? Scientists may finally have the answer. For the first time, researchers have figured out the structure of the sweet receptor the tiny part of your tongue that te.

Research 229

Research 229

ProRelix Research

MAY 11, 2025

Master key regulations and compliance for Nutraceutical Clinical Trials in the USA to ensure trial success and legal safety The nutraceutical industry has witnessed an impressive surge in recent years, […] The post Are You Compliant with Regulations for Nutraceutical Clinical Trials in the USA? appeared first on ProRelix Research.

Clinical Trials 52

Clinical Trials Regulations Trials Compliance 52

New Drug Approvals

MAY 11, 2025

Omaveloxolone CAS 1474034-05-3 N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl]-2,2-difluoropropanamide N -[(4 aS ,6 aR ,6 bS ,8 aR ,12 aS ,14 aR ,14 bS )-11-cyano-2,2,6 a ,6 b ,9,9,12 a -heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8 a ,14 a ,14 b -decahydropicen-4 a -yl]-2,2-difluoropropanamide FDA 2023, 2/28/2023, To treat Friedrichs ataxia Drug Trials Snapshot WeightAverage: 554.723 Monoi

FDA 57

FDA FDA Approval Disease Pharmacokinetics 57

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

New Drug Approvals

MAY 11, 2025

Dasminapant CAS 1570231-89-8 Molecular Weight 1157.40 Formula C 60 H 72 N 10 O 10 S 2 APG-1387, SM-1387, E53VN70K2X, INN 12430 , APG-1387 UNII-E53VN70K2X APG-1387 (SMAC MIMETIC) SMAC-mimetic APG-1387 IAP Inhibitor APG-1387 PYRROLO(1,2-A)(1,5)DIAZOCINE-8-CARBOXAMIDE, 3,3′-(1,3-PHENYLENEBIS(SULFONYL))BIS(N-(DIPHENYLMETHYL)DECAHYDRO-5-(((2S)-2-(METHYLAMINO)-1-OXOPROPYL)AMINO)-6-OXO-, (5S,5’S,8S,8’S,10AR,10’AR)- (5S,5’S,8S,8’S,10aR,10’aR)-3,3′-[1,3-phe

Therapies 62

Therapies Research 62